News

REGN Q2 Deep Dive: New Indications and Pipeline Progress Offset EYLEA Challenges

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% ...

5 Insightful Analyst Questions From Regeneron’s Q2 Earnings Call

Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial ...
PharmiWeb13h

Formycon confirms full-year guidance following business development in line with plan – working capital raised

Half Year Results/Half Year ReportFormycon confirms full-year guidance following business development in line with plan – working capital raised 13.08.2025 / 06:30 CET/CESTThe issuer is solely ...